India to France: Amlodipine Export Trade Route

To import Amlodipine formulations into France, the following approvals and registrations are mandatory:

• Marketing Authorization (MA): A valid MA is required for each medicinal product. Applications must be submitted in the Common Technical Document (CTD) or electronic CTD (eCTD) format.

• Manufacturing/Import Authorization: Entities involved in the manufacture or importation must hold appropriate authorizations, ensuring compliance with Good Manufacturing Practice (GMP) standards.

• GMP Compliance: Manufacturers, including those in India, must demonstrate adherence to EU GMP standards. This involves regular inspections by EU authorities or recognized equivalent bodies.

• GMP Inspection Requirements: Indian manufacturing facilities exporting to France are subject to GMP inspections by EU authorities. Compliance certificates are issued upon successful inspection, confirming adherence to EU GMP standards.

Indian exporters of Amlodipine formulations must comply with the following GMP certifications:

• EU GMP Certification: Manufacturing facilities must be certified under EU GMP guidelines, ensuring products meet the quality standards required for the EU market.

• Current Approved Facilities: The EudraGMDP database lists Indian facilities approved for manufacturing medicinal products for the EU market.

• Recent Inspections and Regulatory Actions: EU authorities, including France's national competent authority, conduct regular inspections of Indian pharmaceutical manufacturers. Non-compliance findings are documented in the EudraGMDP database.

In the past 18 months, several regulatory changes have impacted Indian pharmaceutical exports to France:

• Revision of GMP Annexes: In February 2026, the EMA initiated public consultations for revising Annex 6 (Manufacture of Medicinal Gases) and Annex 15 (Qualification and Validation) of the GMP guidelines. These revisions aim to align with current industry practices and technological advancements.

• International Collaboration: The EMA continues to collaborate with international regulatory bodies to harmonize GMP inspections, enhancing the efficiency of inspections for manufacturers exporting to the EU.

Staying informed about these developments is crucial for Indian exporters to ensure compliance and maintain market access in France.

In 2024, France's pharmaceutical market was valued at approximately €65 billion, with cardiovascular medications, including antihypertensives like Amlodipine, accounting for a significant portion. The prevalence of hypertension in France remains high, affecting about 30% of the adult population, driving consistent demand for antihypertensive treatments. An aging population and universal health coverage further contribute to the sustained need for these medications. While France has a robust domestic pharmaceutical manufacturing sector, it also relies on imports to meet demand. In 2024, France imported finished pharmaceutical formulations containing Amlodipine valued at $15.6 million from India alone, indicating a substantial reliance on external sources.

France imposes a Most-Favored-Nation (MFN) import duty rate of 0.0% on pharmaceutical products classified under HS code 30049072, which includes finished formulations containing Amlodipine. This duty-free status aligns with the European Union's commitment to facilitating access to essential medicines. Additionally, there are no anti-dumping duties or specific free trade agreements between India and France that alter this tariff structure for pharmaceutical imports.

India is a key supplier of Amlodipine formulations to France, with exports totaling $15.6 million in 2024. Other major suppliers include European Union countries and China. India's competitive pricing, driven by cost-effective manufacturing processes, often positions it favorably against European manufacturers. However, exact market share percentages and detailed pricing comparisons require access to comprehensive trade data beyond the provided figures.

India is a global leader in the production of generic pharmaceuticals, accounting for approximately 20% of the global supply by volume as of 2025. This extensive manufacturing capability extends to finished dosage forms containing Amlodipine, including tablets, capsules, and syrups. The country's cost-effective production is driven by economies of scale, a well-established supply chain, and a skilled workforce. As of November 2024, India had 396 facilities approved by the U.S. Food and Drug Administration (FDA), encompassing both Active Pharmaceutical Ingredients (API) and Finished Dosage Forms (FDF) manufacturing. This regulatory endorsement underscores India's commitment to maintaining high-quality standards in pharmaceutical production.

When comparing Amlodipine formulations from India, China, and the European Union (EU), several factors come into play:

• Cost: Indian manufacturers offer Amlodipine formulations at a competitive price point, often lower than their Chinese and EU counterparts. This cost advantage is attributed to India's efficient production processes and lower labor costs.

• Quality Perception: Indian pharmaceutical products are generally well-regarded in international markets, including France. The high number of FDA-approved facilities in India reflects adherence to stringent quality standards.

• Regulatory Acceptance in France: Indian pharmaceutical products are accepted in France, provided they meet the European Medicines Agency (EMA) standards. Many Indian manufacturers have obtained the necessary certifications to export to the EU market.

• Supply Reliability: Indian manufacturers have a strong track record of fulfilling international orders promptly. The country's robust infrastructure and experience in global logistics contribute to this reliability.

The India-France supply chain for Amlodipine formulations is robust, supported by India's substantial manufacturing capacity. For instance, Granules India Limited expanded its finished dosage capabilities by establishing a new facility in Hyderabad, which received FDA approval in November 2025. This facility added an additional 10 billion doses of formulation capacity, a 40% increase over the existing 26 billion dose capacity at their Gagillapur site. Such expansions indicate a commitment to meeting global demand. Indian manufacturers also possess advanced packaging and cold chain capabilities, ensuring product integrity during transit. While there have been instances of regulatory scrutiny, leading companies have taken corrective actions to maintain compliance. Overall, the supply chain remains reliable, with ongoing investments in capacity expansion.

For French buyers sourcing Amlodipine formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions.

• Minimum Order Quantities (MOQs): Be aware that MOQs can vary among suppliers. Establish clear agreements to ensure alignment with your procurement needs.

• Payment Terms: Standard payment terms in India-France pharmaceutical trade often include letters of credit or advance payments. Negotiate terms that balance financial security and cash flow considerations.

• Supplier Qualification Process: Conduct thorough due diligence, including facility audits and compliance checks, to ensure suppliers meet regulatory standards and quality expectations.

• Regulatory Compliance: Ensure that selected suppliers have the necessary certifications for the French market, such as EMA approval, to facilitate smooth importation and distribution.

By meticulously following these guidelines, French pharmaceutical companies can ensure the selection of reliable Indian suppliers for Amlodipine formulations, thereby safeguarding product quality and regulatory compliance.